Promoter Hypermethylation at RASSF1 is a Feature of Small Intestinal Neuroendocrine Tumors Abstract #936

Introduction: Promoter hypermethylation of RASSF1 has been reported in many tumor types.
Aim(s): Unbiased molecular analysis of small intestinal neuroendocrine tumors (SI NETs) has been performed which identified significant differential methylation of RASSF1 between SI NETs and normal tissue.
Materials and methods: Methylation analysis (Infinium HumanMethylation450 Array) was performed on 94 samples from 56 cases; gene expression analysis (HumanWholeGenome DASL Array) was performed on 64 samples from 55 cases; plasma circulating free DNA (cfDNA) hypermethylated RASSF1 detection (methylation sensitive restriction enzyme digestion and RT-PCR) was performed on 12 samples.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr Anna Karpathakis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1227 Molecular Profiling of Small Intestinal Neuroendocrine Tumours (SINETs)
Introduction: Aberrant DNA methylation plays an role in the pathogenesis of many cancers, however little is known about its role in SINET development.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr Anna Karpathakis
#440 The First Neuroendocrine Tumor Methylome Using Methylation-Specific Immunoprecipitation Followed by Second Generation Sequencing – MeDIP-seq
Introduction: Recently, the first cancer methylomes have been created which identified differential methylation at CpG island-shores (2kb upstream of CpG islands) to be of particular importance in the tumourigenic process.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Christina Thirlwell
Authors: Thirlwell C, Sasmaz S, Dibra H, Feber A, ...
#969 Identification of Hypoxia Induced Epigenetic Changes in the Development of Pancreatic Neuroendocrine Tumors
Introduction: In VHL syndrome, pancreatic NETs develop through bi-allelic inactivation of VHL with subsequent HIF pathway activation. This also occurs in sporadic pancreatic NETs.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr Harpreet K Dibra
#2902 DNA Methylation Analysis of the PDX1 Gene Can Be Used for PNET Subtyping and Has a Possible Prognostic Value
Introduction: Estimating prognosis of pancreatic neuroendocrine tumor (PNET) patients remains challenging. Mutation status of DAXX/ATRX/MEN1, histone modification patterns and immunohistochemistry for relevant transcription factors, including PDX1, were recently used to perform subtyping and distinguished two main types, A and B. These subtypes are linked to cell-of-origin and associated with clinical outcome.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Gitta Boons
#2846 Whole Genome DNA Methylation Profiling Identifies Neuroendocrine Tumor Origin
Introduction: Determining the origin of a neuroendocrine tumor (NET) of unknown primary can be challenging. Liver metastases can originate from any organ in the body, while pulmonary NETs can be metastases but also primary tumors. This especially holds true for Multiple Endocrine Neoplasia Type 1 patients, who often have multiple primary pancreatic and intestinal NETs. It is important to know the origin of the primary tumor since resection or ablation is crucial in case of treatment with curative intent. Furthermore, the site of origin determines prognosis, treatment options and eligibility for clinical trials.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Wenzel M Hackeng